SQUAWK/NEWS
Account
Theme
Account
Menu
Live News COMMODITIES FLASH L impact

Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates

Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 ---- Recently published Phase 1b/2 OLVI-VEC-202-SCLC case report extends evidence for Olvi-Vec’s platinum re-sensitization mechanism beyond ovarian cancer to systemic delivery in lung canc…

GNLX

Related stories